Success Stories: Our Expert Legal Team Secures NIW Approval for a Senior Research Assistant from Nepal
Client’s Testimonial:
“There is no word to express my gratitude for your efforts in helping me obtain an I-140 approval.”
On October 17th, 2024, we received another EB-2 NIW (National Interest Waiver) approval for a Senior Research Assistant in the Field of Biomedical Nanotechnology Research (Approval Notice).
General Field: Biomedical Nanotechnology Research
Position at the Time of Case Filing: Senior Research Assistant
Country of Origin: Nepal
State of Residence at the Time of Filing: Texas
Approval Notice Date: October 17th, 2024
Processing Time: 29 days (Premium Processing Requested)
Case Summary:
At North America Immigration Law Group, we recognize that every case is unique, and no case is weaker or stronger than the other. Therefore, we tailor our approach to each client, ensuring the best possible service and experience. When a Senior Research Assistant approached our team to file a National Interest Waiver (NIW) petition, we carefully reviewed his credentials to ensure that his personalized petition highlighted every one of his qualifications and appeared compelling to USCIS.
Upon review, our client holds an M.S. in Biological Sciences, demonstrating his expertise and wide knowledge in the endeavor field. His research has been published in top journals within his field, including 7 peer-reviewed journal articles, 2 conference articles, 6 abstracts, 4 poster presentations, 1 podium presentation, and 3 preprints. In addition to completing and publishing his research, his work has significantly impacted the field, with a total of 47 citations according to Google Scholar.
Furthermore, our client’s work in developing non-invasive imaging platform technology for early detection is pivotal in altering the course of Alzheimer’s and other neurodegenerative diseases in the United States, transforming the management of Alzheimer’s and other neurodegenerative diseases in the United States. His research aims to improve the quality of life for millions of older Americans by reducing the burden of these diseases on the healthcare system.
We received 2 recommendation letters from respected experts that significantly influenced his adjudication process, where one of them wrote:
“This has made him particularly well-suited to addressing the most pressing challenges in neurodegenerative disease detection and treatment, including early diagnosis of Alzheimer’s disease, development of non-invasive imaging biomarkers, and creation of targeted drug delivery systems. It is therefore clear that [Client] is a leader in the field of biomedical nanotechnology research.”
With that said, our client received the good news of his approval in just 29 days. We are pleased to have been part of his journey and would like to thank him for his trust, wishing him continued success in the future.

